Literature DB >> 24513167

Ectopic expression of HOXC6 blocks myeloid differentiation and predisposes to malignant transformation.

Melanie Wurm1, John Kowalski1, Dirk Heckl2, Xiao-Bing Zhang1, Veronica Nelson1, Brian C Beard1,3, Hans-Peter Kiem1,3.   

Abstract

Insertional mutagenesis resulting from the integration of retroviral vectors has led to the discovery of many oncogenes associated with leukemia. We investigated the role of HOXC6, identified by proximal provirus integration in a large animal hematopoietic stem cell gene therapy study, for a potential involvement in hematopoietic stem cell activity and hematopoietic cell fate decision. HOXC6 was overexpressed in the murine bone marrow transplantation model and tested in a competitive repopulation assay in comparison to the known hematopoietic stem cell expansion factor, HOXB4. We have identified HOXC6 as a factor that enhances competitive repopulation capacity in vivo and colony formation in vitro. Ectopic HOXC6 expression also induced strong myeloid differentiation and expansion of granulocyte-macrophage progenitors/common myeloid progenitors (GMPs/CMPs) in vivo, resulting in myeloid malignancies with low penetrance (3 of 17 mice), likely in collaboration with Meis1 because of a provirus integration mapped to the 3' region in the malignant clone. We characterized the molecular basis of HOXC6-induced myeloid differentiation and malignant cell transformation with complementary DNA microarray analysis. Overexpression of HOXC6 induced a gene expression signature similar to several acute myeloid leukemia subtypes when compared with normal GMPs/CMPs. These results demonstrate that HOXC6 acts as a regulator in hematopoiesis and is involved in malignant transformation.
Copyright © 2014 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24513167      PMCID: PMC4062101          DOI: 10.1016/j.exphem.2013.10.004

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  32 in total

1.  GenePattern 2.0.

Authors:  Michael Reich; Ted Liefeld; Joshua Gould; Jim Lerner; Pablo Tamayo; Jill P Mesirov
Journal:  Nat Genet       Date:  2006-05       Impact factor: 38.330

2.  PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors.

Authors:  C Nerlov; T Graf
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

3.  Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b.

Authors:  E Kroon; J Krosl; U Thorsteinsdottir; S Baban; A M Buchberg; G Sauvageau
Journal:  EMBO J       Date:  1998-07-01       Impact factor: 11.598

4.  Meis1 preserves hematopoietic stem cells in mice by limiting oxidative stress.

Authors:  Zeenath Unnisa; Jason P Clark; Jayeeta Roychoudhury; Elizabeth Thomas; Lino Tessarollo; Neal G Copeland; Nancy A Jenkins; H Leighton Grimes; Ashish R Kumar
Journal:  Blood       Date:  2012-10-22       Impact factor: 22.113

5.  PIM1 gene cooperates with human BCL6 gene to promote the development of lymphomas.

Authors:  Beverly W Baron; John Anastasi; Elizabeth M Hyjek; Juraj Bies; Poluru L Reddy; Jingfang Dong; Loren Joseph; Michael J Thirman; Kristen Wroblewski; Linda Wolff; Joseph M Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-26       Impact factor: 11.205

6.  HOXC4, HOXC5, and HOXC6 expression in non-Hodgkin's lymphoma: preferential expression of the HOXC5 gene in primary cutaneous anaplastic T-cell and oro-gastrointestinal tract mucosa-associated B-cell lymphomas.

Authors:  J J Bijl; J W van Oostveen; J M Walboomers; A Horstman; A J van den Brule; R Willemze; C J Meijer
Journal:  Blood       Date:  1997-11-15       Impact factor: 22.113

7.  Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy.

Authors:  Tobias Neff; Brian C Beard; Laura J Peterson; Ponni Anandakumar; Jesse Thompson; Hans-Peter Kiem
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

8.  Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

Authors:  Roel G W Verhaak; Chantal S Goudswaard; Wim van Putten; Maarten A Bijl; Mathijs A Sanders; Wendy Hugens; André G Uitterlinden; Claudia A J Erpelinck; Ruud Delwel; Bob Löwenberg; Peter J M Valk
Journal:  Blood       Date:  2005-08-18       Impact factor: 22.113

9.  Differentiation and cell-type-restricted expression of HOXC4, HOXC5 and HOXC6 in myeloid leukemias and normal myeloid cells.

Authors:  J J Bijl; J W van Oostveen; J M Walboomers; A T Brink; W Vos; G J Ossenkoppele; C J Meijer
Journal:  Leukemia       Date:  1998-11       Impact factor: 11.528

10.  Functional diversity of ESC-derived motor neuron subtypes revealed through intraspinal transplantation.

Authors:  Mirza Peljto; Jeremy S Dasen; Esteban O Mazzoni; Thomas M Jessell; Hynek Wichterle
Journal:  Cell Stem Cell       Date:  2010-09-03       Impact factor: 24.633

View more
  2 in total

1.  Two Receptors, Two Isoforms, Two Cancers: Comprehensive Analysis of KIT and TrkA Expression in Neuroblastoma and Acute Myeloid Leukemia.

Authors:  Timofey D Lebedev; Elmira R Vagapova; Vladimir I Popenko; Olga G Leonova; Pavel V Spirin; Vladimir S Prassolov
Journal:  Front Oncol       Date:  2019-10-18       Impact factor: 6.244

2.  Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.

Authors:  H F Moffett; M E Coon; S Radtke; S B Stephan; L McKnight; A Lambert; B L Stoddard; H P Kiem; M T Stephan
Journal:  Nat Commun       Date:  2017-08-30       Impact factor: 14.919

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.